Time filter

Source Type

Teningen, Germany

Inomed Medizintechnik Gmbh | Date: 2015-08-06

Diagnostic apparatus for medical purposes; surgical apparatus and instruments; urological apparatus and instruments, namely, catheters; probes, electrodes and needles for medical purposes; syringes for medical purposes; electrical controllers and computer monitors being parts for medical apparatus.

Inomed Medizintechnik Gmbh | Date: 2015-02-09

Pressure measuring apparatus; manometers; apparatus for regulating electric current; computer programs for use in the operation of medical apparatus. Diagnostic apparatus for medical purposes; medical and surgical apparatus and instruments for use in neurosurgery, spinal surgery, orthopedic surgery, general surgery, visceral surgery, vascular surgery, and functional neurosurgery; apparatus for washing out body cavities; catheters; probes, electrodes and needles for medical purposes; syringes for medical purposes; computer displays and computer monitors and controllers therefor used in direct connection with medical diagnosis apparatus during the process of diagnosis of a medical condition in an individual. Maintenance, in particular of medical apparatus; repair, namely, of medical apparatus. Scientific and technological services, namely, scientific research, analysis, and testing in the fields of neuromonitoring, visceral surgery, vascular surgery, ear, nose and throat (ENT) medicine, neurosurgery, orthopedics and spinal surgery, functional neurosurgery, neuro diagnostics, psychiatry, and pain therapy; engineering; medical and pharmaceutical research; scientific services; medical research; conducting clinical trials for others; calibration of medical apparatus. Health care for humans; medical services; ambulant medical care; doctors services; medical care; consultancy in relation to surgery; surgical treatments; surgical diagnosis; surgical services; medical assistance; private clinics; hospitals; medical clinic services; medical information; medical treatments; medical consultancy.

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-1.4-1 | Award Amount: 16.14M | Year: 2010

There are currently no cures for Parkinsons disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.

Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2009.3.9 | Award Amount: 11.31M | Year: 2010

The overall concept of the 48-month Integrated Project NEUWalk is focused specifically on Objective ICT-2009.3.9 Microsystems and Smart Miniaturised Systems with particular emphasis to c) Application-specific microsystems and smart miniaturised systems 1) Biomedical S&T objectives. The technological objective of NEUWalk is to develop novel microtechnology, microelectronics, brain decoding algorithms and smart control interfaces that can be flexibly assembled to address neurobiomedical issues that not only impact the quality of life in thousands of individuals throughout Europe, but also create a significant economic burden for European countries. These innovative neurotechnologies will be combined to achieve an integrated cortico-spinal neuroprosthetic interface. The underlying objective in NEUWalk is to restore motor functions in individuals with severe spinal cord injury (SCI) and to establish a more efficient, less invasive and safer strategy to alleviate Parkinsons disease (PD) syndromes. To achieve this ambitious goal, we will capitalize on recent breakthroughs that demonstrate the impressive capacity of spinal cord stimulations to promote the recovery of full weight bearing walking in paralyzed SCI rats and to alleviate severe Parkinsonian symptoms in rodents. Elaboration and validation of the NEUWalk concept will be carried out in rats with SCI and non-human primates with PD. To accelerate the translation towards efficient clinical therapies, preliminary testing will be conducted in humans with SCI. The potential impact of the microtechnology, microelectronics, and treatment paradigms developed in NEUWalk is tremendous. These advances will open avenues for revolutionary clinical applications and will contribute to fill the increasingly wider gap that separates European research on Neuroprosthetics to similar studies conducted in the United States. Beyond SCI and PD, the NEUWalk concepts will fertilize new designs for the treatment of other neurologic disorders.

Discover hidden collaborations